HUP0004747A2 - 2-es helyzetben helyettesített 4-karboxamino-1,2,3,4,-tetrahidrokinolin-származékok és eljárás előállításukra - Google Patents

2-es helyzetben helyettesített 4-karboxamino-1,2,3,4,-tetrahidrokinolin-származékok és eljárás előállításukra

Info

Publication number
HUP0004747A2
HUP0004747A2 HU0004747A HUP0004747A HUP0004747A2 HU P0004747 A2 HUP0004747 A2 HU P0004747A2 HU 0004747 A HU0004747 A HU 0004747A HU P0004747 A HUP0004747 A HU P0004747A HU P0004747 A2 HUP0004747 A2 HU P0004747A2
Authority
HU
Hungary
Prior art keywords
trifluoromethyl
ethyl
quinoline
dihydro
carboxylic acid
Prior art date
Application number
HU0004747A
Other languages
English (en)
Inventor
David Burns Damon
Robert Wyane Dugger
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HU0004747D0 publication Critical patent/HU0004747D0/hu
Publication of HUP0004747A2 publication Critical patent/HUP0004747A2/hu
Publication of HUP0004747A3 publication Critical patent/HUP0004747A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Quinoline Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány szerinti 2-es helyzetben helyettesített 4-karboxiamino-1,2,3,4-tetrahidrokinolinszármazékok koleszteril-észtertranszportproteint gátló anyagok, ezáltal alkalmasak ateroszkleróziskezelésére. A találmány tárgyköréhez tartoznak továbbá a (-)-(2R,4L) -{[3,5-bisz(trifluormetil)benzil]metoxikarbonilamino}-2-etil-6-trifluormetil-3,4-dihidro-2H-kinolin-1-karbonsav-etil-észter, a (-)-(2R,4S)- 4-[3,5-bisz(trifluormetil)benzilamino]-2-etil-6-trifluormetil-3,4-dihidro-2H-kinolin-1-karbonsav-etil-észter-4-toluolszulfonát, a cisz-4-amino-2-etil-6-trifluormetil-3,4-dihidro-2H-kinolin-1-karbonsav-etil-észter, a cisz-(2-etil-6-trifluormetil-1,2,3,4-tetrahidrokinolin-4-il)-karbaminsav-R1-észter - ahol R1jelentése benzil-, terc-butil- vagy alkilcsoport - és a (-)-(2R,4S)-4-{[3,5-bisz(trifluormetil)benzil] metoxikarbonilamino} -2-etil-6-trifluormetil-3,4-dihidro-2H-kinolin-1-karbonsav-etil-észterelőállítására szolgáló eljárások. Ó
HU0004747A 1999-11-30 2000-11-29 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline derivatives and process for their preparation HUP0004747A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16796799P 1999-11-30 1999-11-30

Publications (3)

Publication Number Publication Date
HU0004747D0 HU0004747D0 (hu) 2001-02-28
HUP0004747A2 true HUP0004747A2 (hu) 2001-10-28
HUP0004747A3 HUP0004747A3 (en) 2002-12-28

Family

ID=22609556

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0004747A HUP0004747A3 (en) 1999-11-30 2000-11-29 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline derivatives and process for their preparation

Country Status (45)

Country Link
US (1) US6313142B1 (hu)
EP (1) EP1125929B1 (hu)
JP (1) JP3579345B2 (hu)
KR (1) KR100408177B1 (hu)
CN (1) CN1173953C (hu)
AP (1) AP2000002011A0 (hu)
AR (1) AR029775A1 (hu)
AT (1) ATE315028T1 (hu)
AU (1) AU784694B2 (hu)
BG (1) BG105009A (hu)
BR (1) BR0005636A (hu)
CA (1) CA2327029C (hu)
CO (1) CO5261552A1 (hu)
CY (1) CY1104989T1 (hu)
CZ (1) CZ20004407A3 (hu)
DE (1) DE60025317T2 (hu)
DK (1) DK1125929T3 (hu)
DZ (1) DZ3079A1 (hu)
EA (1) EA003668B1 (hu)
EE (1) EE200000659A (hu)
ES (1) ES2254109T3 (hu)
GE (1) GEP20022798B (hu)
GT (1) GT200000190A (hu)
HK (1) HK1038007A1 (hu)
HN (1) HN2000000203A (hu)
HR (1) HRP20000804A2 (hu)
HU (1) HUP0004747A3 (hu)
ID (1) ID28489A (hu)
IL (1) IL139849A (hu)
IS (1) IS5715A (hu)
MA (1) MA25223A1 (hu)
NO (1) NO20006039L (hu)
NZ (1) NZ508509A (hu)
OA (1) OA11494A (hu)
PA (1) PA8503801A1 (hu)
PE (1) PE20010913A1 (hu)
PL (1) PL344208A1 (hu)
SG (1) SG102603A1 (hu)
SK (1) SK17792000A3 (hu)
TN (1) TNSN00230A1 (hu)
TW (1) TW591016B (hu)
UA (1) UA65615C2 (hu)
UY (1) UY26451A1 (hu)
YU (1) YU71500A (hu)
ZA (1) ZA200006947B (hu)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
WO2003053359A2 (en) 2001-12-19 2003-07-03 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
HUP0500165A2 (en) * 2001-12-19 2006-09-28 Atherogenics Inc Chalcone derivatives and their use to treat diseases
US7279297B2 (en) * 2002-04-11 2007-10-09 Roar Holding Llc Ex vivo method for determination of CETP activity and efficacy of heart disease treatment
BR0315041A (pt) * 2002-10-04 2005-08-16 Millennium Pharm Inc Métodos para inibir crth2 em um indivìduo que necessita inibição de crth2; composto; e composição farmacêutica
US7504508B2 (en) * 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7223870B2 (en) * 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
AU2003303239A1 (en) * 2002-12-19 2004-07-14 Atherogenics, Inc. Process of making chalcone derivatives
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
AU2003283769A1 (en) 2002-12-20 2004-07-14 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
JP2006523218A (ja) * 2003-03-04 2006-10-12 高砂香料工業株式会社 光学活性アミン類の製造方法
MXPA05009848A (es) * 2003-03-17 2005-12-06 Japan Tobacco Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia del ester de colesterilo.
AU2004222436A1 (en) * 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of S-(2-(((1- (2-ethylbutyl) cyclohexyl)carbonyl) amino) phenyl)-2-methylpropanethioate
TWI494102B (zh) * 2003-05-02 2015-08-01 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
KR20060085675A (ko) * 2003-10-08 2006-07-27 일라이 릴리 앤드 캄파니 이상지혈증 치료를 위한 화합물 및 방법
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
EA200700119A1 (ru) * 2004-06-24 2007-10-26 Эли Лилли Энд Компани Соединения и способы лечения дислипидемии
DOP2005000123A (es) 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
US7700774B2 (en) * 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
ZA200707498B (en) * 2005-02-24 2008-11-26 Millennium Pharm Inc PGD2 receptor antagonists for the treatment of inflammatory diseases
TW200808731A (en) 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
CL2008000684A1 (es) 2007-03-09 2008-08-01 Indigene Pharmaceuticals Inc Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica.
CN101429160B (zh) * 2007-11-06 2011-10-19 上海药明康德新药开发有限公司 一种1-r-4-氨基-1,2,3,4-四氢喹啉的合成方法
TWI450896B (zh) 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
TW202409008A (zh) 2022-07-05 2024-03-01 荷蘭商新阿姆斯特丹製藥公司 奧比特拉(obicetrapib)鹽及彼等之製造方法與中間體

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7870M (hu) * 1968-11-08 1970-04-27
US3971789A (en) 1972-10-21 1976-07-27 John Wyeth & Brother Limited O-(4-Quinolylamino)benzamides
GB8432091D0 (en) 1984-12-19 1985-01-30 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
US4839368A (en) 1986-05-02 1989-06-13 Mochida Pharmaceutical Co., Ltd. 1-acyl-2,3-dihydro-4(1H)-quinolinone-4-oxime derivatives
GB8804444D0 (en) 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
US5231102A (en) 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6140342A (en) 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.

Also Published As

Publication number Publication date
CZ20004407A3 (cs) 2002-06-12
JP3579345B2 (ja) 2004-10-20
PL344208A1 (en) 2001-06-04
EA003668B1 (ru) 2003-08-28
ATE315028T1 (de) 2006-02-15
EE200000659A (et) 2001-08-15
JP2001163859A (ja) 2001-06-19
CY1104989T1 (el) 2010-03-03
CA2327029C (en) 2005-08-09
NZ508509A (en) 2001-06-29
GT200000190A (es) 2002-04-27
SK17792000A3 (sk) 2002-10-08
ES2254109T3 (es) 2006-06-16
TW591016B (en) 2004-06-11
US6313142B1 (en) 2001-11-06
SG102603A1 (en) 2004-03-26
KR100408177B1 (ko) 2003-12-01
KR20010052012A (ko) 2001-06-25
ZA200006947B (en) 2002-05-27
NO20006039D0 (no) 2000-11-29
YU71500A (sh) 2003-02-28
HN2000000203A (es) 2001-06-13
AU7178900A (en) 2001-05-31
HK1038007A1 (en) 2002-03-01
IS5715A (is) 2001-05-31
EA200001129A2 (ru) 2001-06-25
PE20010913A1 (es) 2001-09-10
AR029775A1 (es) 2003-07-16
NO20006039L (no) 2001-05-31
BG105009A (en) 2001-11-30
BR0005636A (pt) 2001-07-17
CA2327029A1 (en) 2001-05-30
DZ3079A1 (fr) 2004-10-24
EP1125929A1 (en) 2001-08-22
MA25223A1 (fr) 2001-07-02
HUP0004747A3 (en) 2002-12-28
IL139849A (en) 2006-10-31
DE60025317D1 (de) 2006-03-30
UA65615C2 (uk) 2004-04-15
TNSN00230A1 (fr) 2005-11-10
EA200001129A3 (ru) 2001-10-22
PA8503801A1 (es) 2002-07-30
CN1302800A (zh) 2001-07-11
OA11494A (en) 2004-05-07
EP1125929B1 (en) 2006-01-04
ID28489A (id) 2001-05-31
DE60025317T2 (de) 2006-08-03
HU0004747D0 (hu) 2001-02-28
CN1173953C (zh) 2004-11-03
AU784694B2 (en) 2006-06-01
GEP20022798B (en) 2002-09-25
CO5261552A1 (es) 2003-03-31
IL139849A0 (en) 2002-02-10
AP2000002011A0 (en) 2000-12-31
UY26451A1 (es) 2001-06-29
HRP20000804A2 (en) 2001-06-30
DK1125929T3 (da) 2006-04-03

Similar Documents

Publication Publication Date Title
HUP0004747A2 (hu) 2-es helyzetben helyettesített 4-karboxamino-1,2,3,4,-tetrahidrokinolin-származékok és eljárás előállításukra
CA2473991A1 (en) Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
DE69625690D1 (de) Verfahren zur vorbeugung und behandlung von allergien
DE69431285T2 (de) Herstellungsmethode von markierten genen; transcripten und proteinen
DE59807405D1 (de) Acylsulfamoylbenzoesäureamide, diese enthaltende nutzpflanzenschützende mittel und verfahren zu ihrer herstellung
DE69736443D1 (de) Verfahren zur Behandlung von rostfreien Stahlschlacken
DE69621281T2 (de) Acryl-Säure-Derivate, Verfahren zur Herstellung von Acryl-Säure-Derivaten und Acryl-Säure-Polymere
DE122011100046I1 (de) In vitro kulturprozess fur verschiedene stadien von gewebeparasiten.
DE69939481D1 (de) Methode zur behandlung von diabetes die einen ap2-inhibitor und dazugehörige kombinationen verwendet
DE69927174D1 (de) VERFAHREN ZUM SYNTHETISIEREN VON cDNA
DE69613386D1 (de) Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen
DE60229087D1 (de) VERFAHREN ZUR HERSTELLUNG VON 2-(4-CHLORBENZOYLAMINO-3-i2(1H)-CHINOLINON-4-YL PROPIONSÄURE
DE60323592D1 (de) Verfahren zur Identifizierung von Agenzien zur Behandlung von Anfällen, neurologischen Erkrankungen, Endokrinopathien und hormonalen Erkrankungen
DE69626311D1 (de) Zusammensetzung zur behandlung von wäsche sowie verfahren hierfür
DE60021948D1 (de) Verfahren zur Behandlung von Kontaktlinsen
ATE295311T1 (de) Zweiteiliger kunststoffverschluss und verfahren zum herstellen desselben als einstückiges teil
DE69300508D1 (de) Verfahren und Apparatur zur schnellen und berührungslosen Identifizierung von Holzarten.
ATE338830T1 (de) Verfahren und verarbeitungslinie zum kontinuierlichen strecken von häuten und ähnlichen produkten
ATE180983T1 (de) Verfahren zum abbau von chinolonen und naphthyridonen
DE69307674D1 (de) HIV-Proteaseinhibitoren und ihre Verwendung zur Behandlung von AIDS
ATE250022T1 (de) Verfahren zur oxidation von cycloalkanen, cycloalkoholen und/oder cycloketonen
DE50010234D1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
DE50001329D1 (de) Verfahren und vorrichtung zum formbearbeiten des umfangsrandes von brilllengläsern
DE60001599D1 (de) Verfahren zur Herstellung von cis-1-2-[4-(6-Methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy]ethyl-pyrrolidin
DE69801786D1 (de) Verfahren, Vorrichtung und Produkt zur Verlängerung von menschlichem Haar

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees